Patents by Inventor Ching-Juh Lai

Ching-Juh Lai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150064214
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Application
    Filed: December 4, 2013
    Publication date: March 5, 2015
    Applicant: The USA, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Patent number: 8632782
    Abstract: The invention features novel attenuated dengue virus mutants and compositions thereof.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: January 21, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Publication number: 20130344058
    Abstract: The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (Fc?R) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the Fc region and related nucleic acids, vectors, host cells and methods of producing the variant and methods for preventing or treating a disorder in a mammal.
    Type: Application
    Filed: December 20, 2012
    Publication date: December 26, 2013
    Applicant: The U.S. as represented by the Secretary, Department of Health & Human Services
    Inventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai
  • Publication number: 20130295090
    Abstract: Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies.
    Type: Application
    Filed: July 12, 2013
    Publication date: November 7, 2013
    Inventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai
  • Patent number: 8506961
    Abstract: Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: August 13, 2013
    Assignee: The United States of America as Represented by the Secretary Department of Health and Human Services
    Inventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai
  • Patent number: 8337853
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: December 25, 2012
    Assignee: The United States of America as represented by the Secretary, Department of Health & Human Services
    Inventors: Ching-Juh Lai, Robert H. Purcell
  • Patent number: 8337854
    Abstract: The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (Fc?R) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the Fc region and related nucleic acids, vectors, host cells and methods of producing the variant and methods for preventing or treating a disorder in a mammal.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: December 25, 2012
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai
  • Publication number: 20110033462
    Abstract: Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies.
    Type: Application
    Filed: April 10, 2009
    Publication date: February 10, 2011
    Inventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai
  • Publication number: 20110008256
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: October 27, 2009
    Publication date: January 13, 2011
    Applicant: Government of the US, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ching-Juh Lai, Robert H. Purcell
  • Publication number: 20100247549
    Abstract: The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (Fc?R) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the Fc region and related nucleic acids, vectors, host cells and methods of producing the variant and methods for preventing or treating a disorder in a mammal.
    Type: Application
    Filed: April 3, 2008
    Publication date: September 30, 2010
    Inventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai
  • Patent number: 7622113
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: November 24, 2009
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ching-Juh Lai, Robert H. Purcell
  • Publication number: 20070134256
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize dengue type 1, 2, 3, and/or 4 virus. The invention provides such antibodies, fragments of such antibodies retaining dengue virus-binding ability, fully human or humanized antibodies retaining dengue virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: December 3, 2004
    Publication date: June 14, 2007
    Inventors: Ching-Juh Lai, Robert Purcell
  • Patent number: 6676936
    Abstract: The invention includes a chimeric virus for use in a vaccine preparation having a genome comprising nucleic acid sequences encoding at least one structural protein from one flavivirus and nucleic acid sequences encoding nonstructural protein from another flavivirus. The genome preferably includes mutations within the viral genome that reduce virus virulence and in a particularly preferred embodiment these vaccines are directed to flaviviruses such as dengue virus, tick-borne encephalitis virus and Japanese encephalitis virus. The invention also includes a baculovirus having a recombinant dengue cDNA sequence which encodes: (1) dengue virus capsid protein, pre-matrix protein, envelope glycoprotein and NS1 and NS2a nonstructural proteins or (2) dengue envelope glycoprotein or (3) dengue non-structural proteins NS1 and NS2a.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: January 13, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services.
    Inventors: Ching-Juh Lai, Michael Bray, Alexander G. Pletnev, Ruhe Men, Yi-Ming Zhang, Kenneth H. Eckels, Robert M. Chanock
  • Patent number: 6660273
    Abstract: A live, attenuated chimeric virus vaccine against tick-borne encephalitis virus comprising the preM and E structural genes of the tick-borne encephalitis Langat virus and the non-structural genes of the mosquito-borne dengue virus. The live chimeric vaccine was administered intraperitoneally and exhibited complete attenuation in mice while at the same time providing protection against subsequent challenge with the virulent parental Langat virus.
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: December 9, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Alexander Pletnev, Ruhe Men, Robert Chanock, Ching-Juh Lai
  • Publication number: 20030165539
    Abstract: A live, attenuated chimeric virus vaccine against tick-borne encephalitis virus comprising the preM and E structural genes of the tick-borne encephalitis Langat virus and the non-structural genes of the mosquito-borne dengue virus. The live chimeric vaccine was administered intraperitoneally and exhibited complete attenuation in mice while at the same time providing protection against subsequent challenge with the virulent parental Langat virus.
    Type: Application
    Filed: October 23, 2002
    Publication date: September 4, 2003
    Inventors: Alexander Pletnev, Ruhe Men, Robert Chanock, Ching-Juh Lai
  • Patent number: 6497884
    Abstract: A live, attenuated chimeric virus vaccine against tick-borne encephalitis virus comprising the preM and E structural genes of the tick-borne encephalitis Langat virus and the non-structural genes of the mosquito-borne dengue virus. The live chimeric vaccine was administered intraperitoneally and exhibited complete attenuation in mice while at the same time providing protection against subsequent challenge with the virulent parental Langat virus.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: December 24, 2002
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Alexander Pletnev, Ruhe Men, Robert Chanock, Ching-Juh Lai
  • Patent number: 6184024
    Abstract: The invention includes a chimeric virus for use in a vaccine preparation having a genome comprising nucleic acid sequences encoding at least one structural protein from one flavivirus and nucleic acid sequences encoding nonstructural protein from another flavivirus. The genome preferably includes mutations within the viral genome that reduce virus virulence and in a particularly preferred embodiment these vaccines are directed to flaviviruses such as dengue virus, tick-borne encephalitis virus and Japanese encephalitis virus. The invention also includes a baculovirus having a recombinant dengue cDNA sequence which encodes: (1) dengue virus capsid protein, pre-matrix protein, envelope glycoprotein and NS1 and NS2a nonstructural proteins or (2) dengue envelope glycoprotein or (3) dengue non-structural proteins NS1 and NS2a.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: February 6, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ching-Juh Lai, Michael Bray, Alexander G. Pletnev, Ruhe Men, Yi-Ming Zhang, Kenneth H. Eckels, Robert M. Chanock
  • Patent number: RE45016
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 15, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Patent number: RE45053
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 29, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Patent number: RE45123
    Abstract: The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 9, 2014
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai